Authors

Latest:

Maintenance Strategies After Initial Chemotherapy for Non-Small Cell Lung Cancer

James P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.

James R. Berenson, MD

Latest:

Dr. Berenson Discusses Results from the CHAMPION-1 Trial

James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

James R. Berenson, MD, IMBCR

James R. Berenson, MD, Institute for Myeloma

James R. Jett, MD

Latest:

Dr. Jett on Debates on Molecular Testing for Lung Cancer

James R. Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the most frequent debates surrounding molecular testing for patients with lung cancer.

James Radke

Latest:

Managing Oral Mucositis in Patients With Cancer

One of the most uncomfortable consequences of anticancer therapy is the development of oral mucositis.

James Ryan Mark, MD

Latest:

Dr. Mark on the Use of Degarelix in Men With Prostate Cancer

James Ryan Mark, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the use of degarelix (Firmagon) in the treatment of men with prostate cancer.

James S. Goydos, MD

Latest:

Advanced Squamous Carcinoma of the Skin: A Persistent, Growing Challenge

Advanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.

James Stevenson, MD

Latest:

Dr. Stevenson on the Importance of Early Screening in Lung Cancer

James Stevenson, MD, discusses the importance of early screening in lung cancer.

James T. Thigpen, MD

Latest:

Dr. Thigpen on Ovarian Cancer Drugs Not Approved by FDA

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the use of agents in ovarian cancer that are not approved by the FDA.

James Tate T

James Tate Thigpen, MD, University of Mississippi School of Medicine

James Urbanic, MD

Latest:

Dr. Urbanic on the Evolution of Radiation in NSCLC

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.

James W. Fleshman, Jr., MD

Latest:

Dr. James Fleshman on Minimally Invasive Surgery for Colorectal Cancer

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

James Weitzman, MD

Latest:

Dr. Weitzman on Sequencing Challenges in Myeloma Treatment

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

James Welsh, MD

Latest:

Dr. Welsh on New Understanding of Regulating PD-L1 Expression

James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.

James Wysock, MD

Latest:

Dr. Wysock on the Role of Cytoreductive Nephrectomy in RCC

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma.

James Yang, MD

Latest:

Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLC

James Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.

Jamie E. Chaft, MD

Latest:

Cost-Effectiveness and Closing Perspectives in Early-Stage NSCLC

Panelists discuss how financial toxicity and cost-effectiveness analyses highlight the importance of appropriate patient selection for perioperative immunotherapy, while emphasizing that multidisciplinary care and patient involvement remain essential for optimal outcomes.

Jamie E. Chaft, MD, Memorial Sloan Kettering Cancer Center